Papillary thyroid cancer
Conditions
Interventions
Malignant thyroid nodules, lymph node metastases, BRAFV600E gene mutation group:None
Benign thyroid nodules, non-metastatic lymph nodes, BRAFV600E gene wild group:None
Sponsors
The Fourth Affiliated Hospital of Nanjing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1Patients who underwent total or subtotal thyroidectomy with lymph node dissection between May 2021 and April 2024 at the Fourth Affiliated Hospital of Nanjing Medical University; 2. Postoperative pathological confirmation of papillary or follicular thyroid cancer (malignant) or nodular goiter or thyroid adenoma (benign); 3, Patients who underwent non-enhanced CT (NCCT) neck scan within 1 week before surgery.
Exclusion criteria
Exclusion criteria: 1. Patients with insufficient pathological and laboratory information; 2. Patients younger than 18 years of age; 3 Patients with obvious image artifacts that cannot be analysed.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under curve, AUC;Accuracy, ACC;Sensitivity, SEN;Specificity, SPE; | — |
Secondary
| Measure | Time frame |
|---|---|
| Positive predictive value, PPV;Negative predictive value, NPV;Precision, PRE;Recall, REC;F1 value; | — |
Countries
China
Contacts
Public ContactHao Wang
The Fourth Affiliated Hospital of Nanjing Medical University
Outcome results
None listed